JW SHINYAK CORPORATION Logo

JW SHINYAK CORPORATION

Develops and sells medicines, specializing in dermatology and urology treatments.

067290 | KO

Overview

Corporate Details

ISIN(s):
KR7067290007
LEI:
Country:
South Korea
Address:
경기도 과천시 과천대로7길 38 -, 과천시

Description

JW SHINYAK CORPORATION is a pharmaceutical company engaged in the research, development, production, and sale of medicines and medical supplies. The company specializes in treatments for the clinic market, with a notable focus on dermatology and urology. Its product portfolio includes well-known treatments for hair loss, such as Rogaine and Monad, alongside medications for endocrinology disorders, symptoms related to brain vessel defects, and various bacterial infections. In its research and development activities, JW SHINYAK utilizes proprietary foundational technologies like "DC vacuum technology" and "CTP" to advance its pipeline of bio-medicines. The company also manufactures and distributes a range of healthcare products.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2020-03-11 00:00
[기재정정]의결권대리행사권유참고서류
Korean 111.3 KB
2020-03-10 00:00
[기재정정]주주총회소집결의
Korean 30.8 KB
2020-03-10 00:00
주주총회소집공고
Korean 109.7 KB
2020-03-10 00:00
의결권대리행사권유참고서류
Korean 109.5 KB
2020-03-10 00:00
주주총회집중일개최사유신고
Korean 5.1 KB
2020-02-12 00:00
현금ㆍ현물배당결정
Korean 8.8 KB
2020-02-12 00:00
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 13.8 KB
2020-02-12 00:00
주주총회소집결의
Korean 23.4 KB
2020-01-20 00:00
전환사채(해외전환사채포함)발행후만기전사채취득(제1회차)
Korean 12.1 KB
2020-01-17 00:00
주요사항보고서(타법인주식및출자증권양수결정)
Korean 37.3 KB
2019-12-16 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.3 KB
2019-11-22 00:00
증권발행결과(자율공시)(제3회차 CB)
Korean 6.0 KB
2019-11-21 00:00
주요사항보고서(전환사채권발행결정)
Korean 27.6 KB
2019-11-14 00:00
분기보고서 (2019.09)
Korean 1.1 MB
2019-09-30 00:00
전환가액의조정(제1회차 및 제2회차)
Korean 14.1 KB

Automate Your Workflow. Get a real-time feed of all JW SHINYAK CORPORATION filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for JW SHINYAK CORPORATION

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for JW SHINYAK CORPORATION via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.